NanoViricides, Inc. — Form 10-Q Summary
Reporting period: The filing covers the quarter and nine months ended March 31, 2021, for the fiscal year ending June 30, 2021. This differs from the request metadata labeling the filing “2020 Q3.” The financial statements are unaudited.
Business context
NanoViricides is a pre-revenue antiviral drug-development company. It reported no product sales or revenue. During the period, it prioritized COVID-19 candidates NV-CoV-2 and NV-CoV-2-R; its shingles candidate, NV-HHV-101, and other antiviral programs were secondary priorities. The company relies on intellectual-property licenses and development services from TheraCour Pharma, an entity controlled by its chairman and CEO.
Financial performance and position
| Metric | Three months ended March 31, 2021 | Nine months ended March 31, 2021 | Comparable 2020 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development | $1.46 million | $4.53 million | $1.13 million / $3.63 million |
| General and administrative | $0.64 million | $2.14 million | $1.41 million / $2.54 million |
| Total operating expenses | $2.11 million | $6.67 million | $2.54 million / $6.16 million |
| Net loss | $2.11 million | $6.75 million | $8.08 million / $11.57 million |
| Net loss per share, basic and diluted | $0.19 | $0.63 | $1.24 / $2.45 |
No gross margin or operating margin is meaningful because the company had no revenue. Nine-month operating cash use was $5.99 million, versus $4.96 million in the prior-year period. Investing cash use was $154,122, primarily for property and equipment. Financing provided $15.33 million, including $16.56 million of net common-stock proceeds; the company repaid $1.1 million of related-party mortgage borrowing and made loan payments.
At March 31, 2021, cash and cash equivalents were $22.90 million; current assets were $23.23 million; current liabilities were $871,344; total assets were $32.76 million; and stockholders’ equity was $31.89 million. The related-party mortgage note was repaid in December 2020. The balance sheet showed $165,806 of short-term insurance-premium financing debt. Accumulated deficit was $112.31 million.
Changes versus prior comparable periods
- Quarterly net loss narrowed to $2.11 million from $8.08 million; the nine-month loss narrowed to $6.75 million from $11.57 million. The improvement largely reflects the absence of the prior-year noncash derivative-liability remeasurement loss of $6.12 million for the quarter and $5.85 million for nine months, rather than revenue growth.
- R&D expense increased 29% for the quarter and 25% for nine months, which management attributed to higher outside laboratory fees, laboratory payroll, supplies, and materials.
- G&A expense declined 54% for the quarter and 16% for nine months, primarily due to lower professional fees and operating expenses.
- Cash increased from $13.71 million at June 30, 2020, supported by equity financings. Common shares outstanding rose from 9.08 million to 11.50 million during that period. The company raised approximately $10.4 million net in a July 2020 public offering and $6.1 million net through its ATM offering in March 2021.
Outlook, risks, and notable items
- Management said existing resources were expected to fund planned operations for at least 12 months from issuance of the financial statements, and to cover initial human clinical trials for at least one candidate. It also said further capital will be needed for longer-term operations, clinical trials, and additional programs. No assurance of financing or profitability was given.
- COVID-19 candidates had completed certain preclinical safety pharmacology work; the company was preparing a pre-IND submission and pursuing clinical-trial sites. Management described encouraging cell-culture and animal-study findings, but these are preclinical results, not evidence of human safety or efficacy. Timing of trials remained uncertain, including because of site availability, regulatory review, and pandemic-related disruptions.
- The shingles program had completed IND-enabling safety/toxicology studies, but its progress was deferred while resources focused on COVID-19 and pandemic conditions complicated trial planning.
- The coronavirus license from TheraCour remained under an extended memorandum of understanding, with the full license still being finalized. The related-party relationship, development charges, royalties, and potential milestone obligations merit attention. Accounts payable to TheraCour was reported at $1.07 million before a $491,000 advance offset; the balance-sheet payable was $583,075. The filing also says $200,000 is deferred until an IND filing.
- The company reported no pending or threatened legal proceedings to its knowledge. It disclosed no off-balance-sheet arrangements for the nine-month period.
- Management concluded disclosure controls were not effective as of March 31, 2021 because of an unremediated material weakness previously reported in the 2020 Form 10-K. A financial-reporting controls committee had been established to oversee remediation.
- The filing identifies dependence on TheraCour-licensed intellectual property and external research organizations, potential clinical and regulatory delays, uncertain development costs, future financing needs, and patent and trade-secret risks.
Important facts for investors to verify
- Confirm the reporting-period labeling: the filing itself reports the quarter ended March 31, 2021, not 2020 Q3.
- Track completion of the pre-IND process, FDA feedback, IND submission and clearance, trial-site selection, and actual initiation of human trials.
- Assess the design, replication, and full reports underlying the company’s preclinical claims; do not treat them as demonstrated clinical benefit.
- Monitor cash burn, trial-cost estimates, the remaining availability and use of the $50 million ATM facility, and potential future share dilution.
- Review the final coronavirus license terms with TheraCour, related-party balances and charges, and any milestone, royalty, or other payment obligations.
- Follow remediation of the disclosed material weakness and any subsequent changes in internal controls.